Great advances in cancer care have led to a new phase of research in certain cancers – in areas where a high rate of cure has been established, the focus is shifting to quality of life, sid
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.